SGLT-2 Inhibitor use is Associated with Lower Mortality in Patients with Alcoholic Cirrhosis and Type 2 Diabetes Mellitus: A Multinational Analysis

Authors

Do Han Kim MD, Department of Medicine, Mount Sinai Morningside and West, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Donghyun Ko, Department of Internal Medicine, Bridgeport Hospital, Yale New Haven Health, Bridgeport, CT, USA.Follow
Jose A. Porres, Universidad Francisco Marroquin, Guatemala City, Guatemala.
Wilhelm S. Basegoda MD, University of South Alabama, Mobile, AL, USA
Cristina H. Makarian, Universidad Francisco Marroquín, Facultad de Medicina, Guatemala City, Guatemala
Luis M. Nieto MD, Division of Gastroenterology and Hepatology, Emory University, Atlanta, GA, USA.
Pedro Palacios Argueta MD, Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, Philadelphia, PA, USA
Paul T. Kroner MD, Department of Gastroenterology, Riverside Health System, Newport News, VA, USA.
Frank J. Lukens MD, Division of Gastroenterology and Hepatology, Mayo Clinic Florida, Jacksonville, FL, USA

Document Type

Conference Proceeding

Abstract

In our study, we aimed to investigate whether SGLT2 inhibitors are associated with a reduced risk of all-cause mortality, liver-related events, and cardiovascular outcomes in patients with alcoholic cirrhosis and T2DM.

Publication Date

5-2025

Recommended Citation

Kim, Do Han MD; Ko, Donghyun; Porres, Jose A.; Basegoda, Wilhelm S. MD; Makarian, Cristina H.; Nieto, Luis M. MD; Palacios Argueta, Pedro MD; Kroner, Paul T. MD; and Lukens, Frank J. MD, "SGLT-2 Inhibitor use is Associated with Lower Mortality in Patients with Alcoholic Cirrhosis and Type 2 Diabetes Mellitus: A Multinational Analysis" (2025). Posters. 92.
https://scholar.bridgeporthospital.org/poster_presentations/92